不同驱动基因突变晚期非小细胞肺癌患者免疫治疗疗效及预后影响因素分析( 六 ) _健康小知识

GuisierF,Dubos-ArvisC,Vi?asF,etal.Efficacyandsafetyofanti-PD-1immunotherapyinpatientswithadvancedNSCLCwithBRAF,HER2,orMETmutationsorRETtranslocation:GFPC01-2018[J].JThoracOncol,2020,15(4):628-636.DOI:10.1016/j.jtho.2019.12.129.
SabariJK,LeonardiGC,ShuCA,etal.PD-L1expression,tumormutationalburden,andresponsetoimmunotherapyinpatientswithMETexon14alteredlungcancers[J].AnnOncol,2018,29(10):2085-2091.DOI:10.1093/annonc/mdy334.
DudnikE,PeledN,NechushtanH,etal.BRAFmutantlungcancer:programmeddeathligand1expression,tumormutationalburden,microsatelliteinstabilitystatus,andresponsetoimmunecheck-pointinhibitors[J].JThoracOncol,2018,13(8):1128-1137.DOI:10.1016/j.jtho.2018.04.024.
RittmeyerA,BarlesiF,WaterkampD,etal.Atezolizumabversusdocetaxelinpatientswithpreviouslytreatednon-small-celllungcancer(OAK):aphase3,open-label,multicentrerandomizedcontrolledtrial[J].Lancet,2017,389(10066):255-265.DOI:10.1016/S0140-6736(16)32517-X.
HerbstRS,BaasP,KimDW,etal.Pembrolizumabversusdocetaxelforpreviouslytreated,PD-L1-positive,advancednon-small-celllungcancer(KEYNOTE-010):arandomisedcontrolledtrial[J].Lancet,2016,387(10027):1540-1550.DOI:10.1016/S0140-6736(15)01281-7.
LeeCK,ManJ,LordS,etal.Clinicalandmolecularcharacteristicsassociatedwithsurvivalamongpatientstreatedwithcheckpointinhibitorsforadvancednon-smallcelllungcarcinoma:asystematicreviewandmeta-analysis[J].JAMAOncol,2018,4(2):210-216.DOI:10.1001/jamaoncol.2017.4427.
LeeCK,ManJ,LordS,etal.CheckpointinhibitorsinmetastaticEGFR-mutatednon-smallcelllungcancer-ameta-analysis[J].JThoracOncol,2017,12(2):403-407.DOI:10.1016/j.jtho.2016.10.007.
GarassinoMC,ChoBC,KimJH,etal.Durvalumabasthird-lineorlatertreatmentforadvancednon-small-celllungcancer(ATLANTIC):anopen-label,single-arm,phase2study[J].LancetOncol,2018,19(4):521-536.DOI:10.1016/S1470-2045(18)30144-X.
GettingerS,HellmannMD,ChowL,etal.NivolumabplusErlotinibinpatientswithEGFR-mutantadvancedNSCLC[J].JThoracOncol,2018,13(9):1363-1372.DOI:10.1016/j.jtho.2018.05.015.
OxnardGR,YangJC,YuH,etal.TATTON:amulti-arm,phaseⅠbtrialofosimertinibcombinedwithselumetinib,savolitinib,ordurvalumabinEGFR-mutantlungcancer[J].AnnOncol,2020,31(4):507-516.DOI:10.1016/j.annonc.2020.01.013.
WestH,McCleodM,HusseinM,etal.Atezolizumabincombinationwithcarboplatinplusnab-paclitaxelchemotherapycomparedwithchemotherapyaloneasfirst-linetreatmentformetastaticnon-squamousnon-small-celllungcancer(IMpower130):amulticentre,randomised,open-label,phase3trial[J].LancetOncol,2019,20(7):924-937.DOI:10.1016/S1470-2045(19)30167-6.
JiangT,WangP,ZhangJ,etal.Toripalimabpluschemotherapyassecond-linetreatmentinpreviouslyEGFR-TKItreatedpatientswithEGFR-mutant-advancedNSCLC:amulticenterphase-Ⅱtrial[J].SignalTransductTargetTher,2021,6(1):355.DOI:10.1038/s41392-021-00751-9.
ReckM,MokT,NishioM,etal.Atezolizumabplusbevacizumabandchemotherapyinnon-small-celllungcancer(IMpower150):keysubgroupanalysesofpatientswithEGFRmutationsorbaselinelivermetastasesinarandomised,open-labelphase3trial[J].LancetRespirMed,2019,7(5):387-401.DOI:10.1016/S2213-2600(19)30084-0.
KimJH,KimHS,KimBJ.PrognosticvalueofKRASmutationinadvancednon-small-celllungcancertreatedwithimmunecheckpointinhibitors:ameta-analysisandreview[J].Oncotarget,2017,8(29):48248-48252.DOI:10.18632/oncotarget.17594.
更多免费用药机会看这里！
【不同驱动基因突变晚期非小细胞肺癌患者免疫治疗疗效及预后影响因素分析】30年数据揭秘癌症真相：为何身边越来越多人患癌？
患者受益|重磅！晚期非小细胞肺癌患者有新希望！
靶向药物时代兴起，肿瘤患者应如何应对肝损伤？
不想活了，真的太痛了！癌痛到底有多痛？只能忍着吗？
患者招募|非小细胞肺癌患者|YK-029A
肺癌两年化疗联合“K药”免疫治疗，强强联手患者生存期有效延长
一文详解|免疫治疗在EGFR突变非小细胞肺癌中的相关研究进展
———————END———————